NHS Approves New GIST Cancer Drug After 3 Treatments Fail

Patients in England with advanced gastrointestinal stromal tumors now have a fourth treatment option after NHS approved ripretinib, a drug that extends life with fewer side effects.

For those who've exhausted all other therapies and faced weeks to live, this approval brings genuine hope.